INNOVIVA, INC. Investment Income, Amortization of Premium
INNOVIVA, INC. (INVA) reported Investment Income, Amortization of Premium of -$3.00 thousand for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-05.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeAmortizationOfPremium · last filed 2016-05-05
- INNOVIVA, INC. investment income, amortization of premium for the quarter ending 2016-03-31 was -$3.00K, a 101.29% decline year-over-year.
- INNOVIVA, INC. investment income, amortization of premium for the quarter ending 2015-12-31 was $57.00K, a 71.92% decline year-over-year.
- INNOVIVA, INC. investment income, amortization of premium for the quarter ending 2015-09-30 was $134.00K, a 5.51% increase year-over-year.
- INNOVIVA, INC. investment income, amortization of premium for the quarter ending 2015-06-30 was $159.00K, a 75.54% decline year-over-year.
- INNOVIVA, INC. investment income, amortization of premium for fiscal 2015 was $583.00K, a 66.53% decline from fiscal 2014.
- INNOVIVA, INC. investment income, amortization of premium for fiscal 2014 was $1.74M, a 54.09% decline from fiscal 2013.
- INNOVIVA, INC. investment income, amortization of premium for fiscal 2013 was $3.79M, a 16.81% increase from fiscal 2012.
- INNOVIVA, INC. investment income, amortization of premium for fiscal 2012 was $3.25M.
| Period end | Investment Income, Amortization of Premium 3 month | Investment Income, Amortization of Premium 6 month | Investment Income, Amortization of Premium 9 month | Investment Income, Amortization of Premium 12 month |
|---|---|---|---|---|
| 2016-03-31 | -$3.00K 10-Q · filed 2016-05-05 | $54.00K derived: sum of 2 quarters · filed 2016-05-05 | $188.00K derived: sum of 3 quarters · filed 2016-05-05 | $347.00K derived: sum of 4 quarters · filed 2016-05-05 |
| 2015-12-31 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $191.00K derived: sum of 2 quarters · filed 2016-02-24 | $350.00K derived: sum of 3 quarters · filed 2016-02-24 | $583.00K 10-K · filed 2016-02-24 |
| 2015-09-30 | $134.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $293.00K derived: sum of 2 quarters · filed 2015-11-05 | $526.00K 10-Q · filed 2015-11-05 | $729.00K derived: sum of 4 quarters · filed 2016-05-05 |
| 2015-06-30 | $159.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $392.00K 10-Q · filed 2015-08-06 | $595.00K derived: sum of 3 quarters · filed 2016-05-05 | $722.00K derived: sum of 4 quarters · filed 2016-05-05 |
| 2015-03-31 | $233.00K 10-Q · filed 2016-05-05 | $436.00K derived: sum of 2 quarters · filed 2016-05-05 | $563.00K derived: sum of 3 quarters · filed 2016-05-05 | $1.21M derived: sum of 4 quarters · filed 2016-05-05 |
| 2014-12-31 | $203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $330.00K derived: sum of 2 quarters · filed 2016-02-24 | $980.00K derived: sum of 3 quarters · filed 2016-02-24 | $1.74M 10-K · filed 2016-02-24 |
| 2014-09-30 | $127.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $777.00K derived: sum of 2 quarters · filed 2015-11-05 | $1.54M 10-Q · filed 2015-11-05 | $2.40M derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-06-30 | $650.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $1.41M 10-Q · filed 2015-08-06 | $2.27M derived: sum of 3 quarters · filed 2016-02-24 | $3.35M derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-03-31 | $762.00K 10-Q · filed 2015-05-08 | $1.62M derived: sum of 2 quarters · filed 2016-02-24 | $2.70M derived: sum of 3 quarters · filed 2016-02-24 | |
| 2013-12-31 | $861.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $1.94M derived: sum of 2 quarters · filed 2016-02-24 | $3.79M 10-K · filed 2016-02-24 | |
| 2013-09-30 | $1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $2.93M 10-Q · filed 2014-11-04 | ||
| 2013-06-30 | $1.85M 10-Q · filed 2014-08-07 | |||
| 2012-12-31 | $3.25M 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |